Autoimmunity: The Fas track  by Rathmell, Jeffrey C. & Goodnow, Christopher C.
JEFFREY C. RATHMELL AND CHRISTOPHER C. GOODNOW
The Fas track
The discovery of mutations in the gene encoding Fas in patients with an
autoimmune lymphoproliferative syndrome, and studies of Fas-deficient
mice provide the first molecular view of the pathogenesis of autoimmunity.
Foreign microorganisms are the normal targets of anti-
bodies, but in approximately 5 % of us the capacity of the
immune system to distinguish foreign from self breaks
down, resulting in antibody production against our own
tissues. The targets of autoimmune attack can be
restricted to very specific elements of our bodies, such as
the insulin-producing beta cells of the pancreas in Type I
diabetes, or they can be fundamental building blocks of
every tissue, such as DNA and chromatin which become
targets of autoantibodies in systemic lupus erythematosus
(SLE). What goes wrong in the subset of people that
develop autoimmune disease?
Cellular processes that normally prevent self-reactive
lymphocytes from initiating antibody responses have at,
last come into view (Fig. 1), but until very recently noth-
ing has been known of the molecular circuitry underpin-
ning these important self-tolerance processes. Inherited
faults in these molecular circuits nevertheless appear to be
a key factor determining susceptibility or resistance to
autoimmune disease, as diseases like Type I diabetes and
SLE often run in families and have an elevated con-
cordance in identical twins. The existence of mouse
strains that inherit a high predisposition to autoimmune
disease bears out the importance of genetic makeup in
the development of autoimmunity. Pinpointing the mol-
ecules affected by these heritable differences has been
difficult, however, because multiple genes appear to con-
tribute to the cumulative risk of autoimmune disease in a
complex manner.
Extraordinary progress in the last few years is now provi-
ding a striking view of an essential molecular circuit for
maintaining self-tolerance, highlighted by two landmark
papers published in recent issues of Science and Cell.
Rieux-Laucat et al. [1] and Fisher et al. [2] independently
describe' a total of eight children with an unusual and
severe autoimmune disorder that is almost certainly due
in part to their having inherited genes encoding defective
versions of a lymphocyte cell-surface protein called Fas
(also known as APO-1 or CD95). A picture of how Fas
normally works to prevent autoimmunity is becoming
clear, as described below, providing the first detailed
view of the process dubbed by Ehrlich in 1900 as 'horror
autotoxicus'.
A remarkable convergence between mouse genetics and
human tumor immunology has led to the identification
of Fas as a lynchpin in resistance to autoimmune disease
[3]. In 1976, mouse geneticists at the Jackson Laborato-
ries described a spontaneous recessive mutation, lympho-
proliferation (pr), which resulted in the production of
autoantibodies against DNA and chromatin, much as
occurs in human SLE [4]. The lpr mutation also caused
Fig. 1. Multiple checkpoints prevent
autoantibody production. Individual
checkpoints affecting B and T lympho-
cytes are labeled in red triangles. 1:
elimination of B and T lymphocytes dur-
ing their formation in primary lymphoid
organs such as bone marrow and thy-
mus. 2: elimination of self-reactive B
cells by competitive exclusion from fol-
licular niches and from the recirculating
pool of mature B cells. 3: inactivation
(anergy) of self-reactive T cells stimu-
lated by antigen in the absence of
immunogenic co-stimuli such as B7.1
and B7.2. 4: Fas-dependent elimination
of self-reactive T cells that become acti-
vated by self-antigen and bystander T
cells. 5: inactivation (anergy) of self-
reactive B cells by antigen-receptor
modulation and desensitization. 6: Fas-
dependent elimination of self-reactive B
cells that become activated by present-
ing self-antigen to CD4 + T cells. 7: Fas-
dependent and Fas-independent mechanisms that eliminate the majority of activated lymphocytes at the end of an immune response.
8: elimination of self-reactive B cells that arise by somatic hypermutation of antigen-receptor genes in germinal centers. 9: self-antigen
induced interference with terminal differentiation into plasma cells.
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Fig. 2. A model for autoantibody production in Fas-deficient individuals. When the Fas signalling pathway is disrupted, self-reactive T
cells which have been stimulated by their T-cell receptor (TCR) and interleukin 2 (IL-2), but not by CD28 or other immunogenic co-stim-
uli, avoid apoptosis and instead proliferate. When self-reactive B cells present self-antigen to these T cells, both Fas-ligand and CD40-
ligand are displayed on the T cell. Because the antigen receptors (BCRs) on self-reactive B cells are desensitized by chronic exposure to
self-antigen, the Fas death signal dominates and causes the B cell to undergo apoptosis. When the Fas pathway is disrupted by mutation
in Fas or another molecule in this pathway, CD40 can deliver a mitogenic signal to the B cell and cause it to proliferate.
massive enlargement of lymph nodes by unusual
CD4- CD8- T lymphocytes, a feature not usually seen in
SLE. This characteristic of Ipr mice appears not to con-
tribute to autoantibody production [5,6]. Although the
severity and penetrance of pr-associated autoantibodies
and disease depends on genetic background [4], the fact
that Ipr was sufficient to cause autoimmunity essentially as
a single-gene recessive trait facilitated both its chromo-
somal mapping and the construction of congenic mouse
strains for powerful functional analyses (see below). An
independent, complementing mutation with very similar
characteristics and location, IprCg, was subsequently
described in a subline of mice in Japan [7].
In the late 1980s, tumor immunologists in Germany and
Japan independently described monoclonal antibodies
with the unusual property of triggering rapid lymphoma-
cell death upon binding a molecule on the surface of
human lymphoma cells [8,9]. Molecular cloning revealed
that the antigens, APO-1 and Fas, were identical and
represented a membrane-spanning protein homologous
to the receptors for tumor necrosis factor (TNF) and
nerve growth factor (NGF), now known to be part of a
large family of receptors [10,11]. The human Fas gene
mapped to a chromosomal region that was syntenic with
the region in the mouse genome known to contain Ipr,
and transcription of the mouse Fas gene was indeed
found to be defective in Ipr mice [12]. Most tellingly, the
Iprg mutation was found to be a single amino-acid sub-
stitution in the cytoplasmic tail of Fas [12], in a site that
has been defined as the 'death domain' based on func-
tional studies of conserved regions in Fas and a related
molecule, the TNF receptor, in cultured cells [3].
The children described by Rieux-Laucat et al. [1] and
Fisher et al. [2] carry analogous Fas mutations and have
broadly similar symptoms to lpr mice, including both
autoantibody production (although primarily to erythro-
cytes and platelets rather than chromatin) and lymph-
node enlargement with unusual CD4- CD8- T lympho-
cytes [1,2]. Several of the patients were unable to produce
a stable cell-surface protein from their mutant Fas allele.
Others produced truncated Fas molecules missing the
death domain that, in one study, acted in a dominant-
negative manner by interfering with cell-death induction
by wild-type Fas upon expression in cultured cells. Lym-
phocytes from each of the children were inefficiently trig-
gered into cell death by antibodies to Fas, compared with
lymphocytes from disease-free siblings or parents.
Interestingly, two mothers of such children were found
to express a dominant-negative mutant Fas [2], while
another mother expressed a similar potentially dominant-
negative mutant Fas [1], but in each case the mothers
exhibited no disease [1,2]. Conversely, a disease-free
father displayed a defect in Fas-mediated apoptosis in
vitro, despite his having no Fas defect, prompting specula-
tion that he carried other genetic defects in the Fas path-
way and transmitted these to his children to increase the
penetrance of the heterozygous Fas mutation inherited
from the mother [1]. These findings harken back to
mouse studies showing that autoimmune disease in lpr
animals is in fact a polygenic disorder, with other genes
playing a major role in modifying the penetrance and
severity of autoantibody production [4,7].
What does Fas do that is so crucial for maintaining self-
tolerance to fundamental building blocks like erythro-
cytes, platelets and DNA? Elegant studies of chimeric
mice, constructed with mixtures of cells from congenic
Ipr and wild-type donors whose lymphocytes and anti-
body products could be distinguished by allelic markers,
1220 Current Biology 1995, Vol 5 No 11
have established that autoantibody production results
only from B cells that are deficient in Fas, and only when
Fas-deficient T cells are also present [13-15]. CD4+ T
cells, which normally interact with B cells to promote
antibody production against foreign microorganisms,
were shown to be the necessary T-cell subset for autoan-
tibody production in lpr animals [6]. These results,
together with the need for a functional death domain in
Fas, imply that Fas plays its essential role in self-tolerance
by signaling the death of B and T lymphocytes.
When and where does Fas-mediated death of B and T
cells occur to prevent autoimmune disease? An important
fraction of B and T cells whose antigen receptors happen
to bind to normal self-constituents are indeed eliminated
by undergoing cell death soon after their formation in
the bone marrow and thymus (Fig. 1) [16,17]. Despite
the fact that Fas is expressed by thymic T cells, elimina-
tion of self-reactive T and B cells in these primary lym-
phopoietic organs appears not to be perturbed when the
cells carry defective Fas genes [18-20].
Not all self-reactive lymphocytes are purged in the
primary lymphopoietic organs, however, and the remain-
der are exported to the peripheral lymph nodes and.
spleen, where immune responses against foreign microor-
ganisms are normally initiated. It is in these sites that
defects caused by Fas deficiency become apparent. CD4+
T cells that become activated upon binding an antigen in
peripheral lymphoid tissues normally begin dividing to
form an expanded clone, and at some point this expan-
sion process is halted and corrected by death of the acti-
vated T cells (Fig. 1) [21-23]. Russell et al. [24] were the
first of many to report a defect in this activation-induced
cell death in Ipr T cells. It is now clear that this comes
about by an autocrine or paracrine process involving the
simultaneous expression of Fas and its ligand, FasL, on
activated T cells [3, 25-27].
The clonal expansion of CD4+ T cells that carry defec-
tive versions of Fas cannot be checked by this process,
potentially allowing these cells to promote autoantibody
production by self-reactive B cells. It is not yet known
if Fas controls self-reactive CD4+ T cells in peripheral
lymphoid tissues, or simply curtails T-cell responses to
foreign antigens. The finding that Fas may preferentially
induce death of those T cells that become activated by
antigens in the absence of certain co-stimulatory signals,
such as B7 or TNF [20,28,29], nevertheless argues for a
role in self-tolerance, as self antigens are normally
encountered by T cells in the absence of these co-stimuli,
whereas foreign microorganisms carry powerful triggers
for co-stimulus production.
A direct role for Fas in eliminating self-reactive B cells in
peripheral lymphoid tissues has recently been demon-
strated. Rathmell et al. [30] found that self-reactive B cells
that reach the spleen in a state of anergy - in which their
antigen receptors can no longer transmit an activating sig-
nal - present self antigen to CD4+ T cells, but are killed
instead of the usual outcome of clonal expansion and
antibody secretion. Elimination of self-reactive B cells by
this route depends on Fas expression by the B cells, and
on normal FasL expression by the T cells; when either of
these molecules are deficient, self-reactive B cells escape
being killed by T cells and proceed to proliferate [30].
An explanation for why anergic B cells might be killed
by CD4+ T cells, whereas B cells that have been acutely
activated by antigen proliferate, comes from in vitro stud-
ies by Rothstein et al. [31]. They demonstrated that naive
B cells become highly susceptible to Fas-mediated killing
when they are stimulated through CD40, a key receptor
on the B cell for T-cell help, but that concurrent antigen-
receptor engagement on the B cell in some way prevents
transmission of the Fas death signal. Acute crosslinking of
the B cell's antigen receptors, as would occur soon after
an infection, may thus protect the B cell from Fas-
triggered death. By contrast, chronic receptor engage-
ment by ubiquitous self antigens desensitizes the B cell's
antigen receptors and renders the cell vulnerable to
Fas-triggered death [30].
Are these twin defects sufficient to explain autoimmunity
and the production of autoantibodies in Fas-deficient
mice and humans? The requirement for simultaneous
defects in both B- and T-cell lineages [13-15] provides a
strong foundation from which the results described above
can be assembled into a model of autoimmunity caused
by defects in Fas-dependent tolerance checkpoints (Fig.
2). Autoreactive CD4+ T cells that escape thymic censor-
ing, for example because of insufficient exposure to
autoantigen, can potentially be stimulated by autoanti-
gens in the periphery. Normally these cells may pose
little risk because autoantigen stimulation is not accom-
panied by co-stimuli, such as the B7 ligands for CD28,
that are needed to produce enough interleukin 2 (IL-2)
for clonal expansion. If sufficient IL-2 is received from
neighboring T cells [22], however, Fas may then play a
key role in aborting the autoreactive T cell because of the
missing CD28 or TNF co-stimuli [28,29].
The activation of Fas-deficient autoreactive T cells can-
not be aborted by this route, and instead they continue to
be stimulated by self-antigen and proliferate. When
autoreactive B cells present self antigens to these rogue T
cells, the T cells display on their surface both the CD40
ligand (CD40L) and FasL. Normally, the Fas signal
would trigger the death of the self-reactive B cell because
of the lack of antigen-receptor signalling from their
desensitized receptors. If the B cells are Fas deficient,
however, they too escape death and instead are stimulated
by CD40 to proliferate. As the surviving B and T cells
continue to interact and form expanded forbidden
clones, some of the B cells differentiate into plasma cells
that produce autoantibodies.
A key question that remains unanswered concerns the
genes that modify the severity and penetrance of Fas-asso-
ciated disease. For example, why do only some carriers of
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the Fas defects described by Rieux-Laucat et al. [1] and
Fisher et al. [2] develop autoimmune disease, and why do
lpr mice only develop certain autoantibodies and disease
after a long latent period that is strongly influenced by
other genes [4]? By analogy with inherited susceptibility
to cancer, other defects in the Fas circuit or in other
checkpoints for censoring self-reactive cells, such as ger-
minal-center elimination of B cells or negative selection
of thymocytes (Fig. 1), may need to be present either as
inherited alleles or as somatically acquired mutations [7].
Finally, while most individuals with SLE probably do not
carry defective copies of Fas, it remains to be explored
whether other genes in the circuit are faulty. The example
of Fas defects thus provides an entry point into the mol-
ecular anatomy of autoimmunity and a paradigm for how
mouse genetics and human clinical research can be
brought to bear on this fundamental problem.
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